Shire News

34,49 +1,20% +0,41 €
22.02.18 Tradegate | Mehr Kurse »
WKN: A0MMAG
ISIN: JE00B2QKY057
US-Symbol: SHPGF
Typ: Aktie

Shire News

Do Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis GlobeNewswire
15.02.18 Diageo, Shire und BP: Aktuelle Trendsignale Finanztrends
14.02.18 Shire plc : Final Results GlobeNewswire
02.02.18 Royal Bank of Scotland, Lloyds Banking und Shire: Aktuelle Trendsignale Finanztrends
30.01.18 AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program GlobeNewswire
24.01.18 FDA Grants Approval to Shire for Technology Transfer of CINRYZE® Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site GlobeNewswire
08.01.18 Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
04.01.18 Shire to present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
27.12.17 Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise GlobeNewswire
13.12.17 Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) GlobeNewswire
05.12.17 Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill(TM) Technology for the Oral Delivery of Factor Therapy GlobeNewswire
01.12.17 Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer GlobeNewswire
30.11.17 U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-​MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients GlobeNewswire
20.11.17 Shire plc : Directorate change GlobeNewswire
13.11.17 CHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A GlobeNewswire
10.11.17 Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology GlobeNewswire
27.10.17 Shire plc : 3rd Quarter Results GlobeNewswire
26.10.17 Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients GlobeNewswire
25.10.17 Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A GlobeNewswire
19.10.17 Create the Soundtrack to Your Unique Day with "Compose Your Life" PR Newswire
13.10.17 Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) GlobeNewswire
20.09.17 Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD GlobeNewswire
12.09.17 Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants GlobeNewswire
11.09.17 Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial GlobeNewswire
07.09.17 Shire to participate at two upcoming investor conferences GlobeNewswire
22.08.17 Shire plc : Director/PDMR Shareholding GlobeNewswire
21.08.17 Shire plc Director and Senior Management Changes GlobeNewswire
15.08.17 Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe GlobeNewswire
03.08.17 Shire plc : Shire reports strong Q2 2017 operating results and cash flow GlobeNewswire
06.07.17 Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A GlobeNewswire
23.06.17 SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA GlobeNewswire
22.06.17 SHIRE PLC - Director Declaration PR Newswire
22.06.17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease PR Newswire
22.06.17 Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease PR Newswire
21.06.17 SHIRE PLC - Regulatory Approval PR Newswire
20.06.17 Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-​Entity Amphetamine Product) - A New Once-​Daily Option for ADHD Symptom Control in Patients 13 Years and Older PR Newswire
07.06.17 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shire plc - SHPG PR Newswire
01.06.17 SHIRE PLC - Director/PDMR Shareholding PR Newswire
01.06.17 SHIRE PLC - Total Voting Rights PR Newswire
25.05.17 Shire to Participate at the Jefferies Healthcare Conference PR Newswire
23.05.17 SHIRE PLC - Blocklisting - Interim Review PR Newswire
19.05.17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology PR Newswire
19.05.17 Shire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology PR Newswire
18.05.17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-​MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-​to-Severe Ulcerative Colitis PR Newswire
18.05.17 The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-​MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-​to-Severe Ulcerative Colitis PR Newswire
18.05.17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial PR Newswire
18.05.17 SHIRE PLC - Positive lanadelumab topline Phase 3 results PR Newswire
18.05.17 Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial PR Newswire
16.05.17 Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association PR Newswire
03.05.17 SHIRE PLC - Director/PDMR Shareholding PR Newswire

Newssuche